SCHEMBL407763

SCHEMBL407763

[O]C(=O)c1cc(O)c(O)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.62
LMNA P02545 3/20 0.62
TDP1 Q9NUW8 3/20 0.62
ALDH1A1 P00352 2/20 0.62
MAPT P10636 2/20 0.62
FUT7 Q11130 2/20 0.62
CA12 O43570 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
TP53 P04637 1/20 0.62
CA3 P07451 1/20 0.62
SELL P14151 1/20 0.62
HPGD P15428 1/20 0.62
SELP P16109 1/20 0.62
FUT4 P22083 1/20 0.62
CA4 P22748 1/20 0.62
CA6 P23280 1/20 0.62
DPP4 P27487 1/20 0.62
MAPK1 P28482 1/20 0.62
CA5A P35218 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gallic Acid SCHEMBL28200674 0.80 CA12 (0.94) KDM4ELMNATDP1ALDH1A1MAPT
SCHEMBL561936 0.79 PTGS2 (0.71) KDM4ELMNATDP1ALDH1A1FUT7
SCHEMBL352369 0.79 KDM4E (0.65) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL617137 0.78 KDM4E (0.56) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL15012 0.77 CA12 (1.00) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL1845406 0.77 CA12 (1.00) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL30375631 0.77 CA12 (1.00) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL4918056 0.77 CA12 (1.00) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL678990 0.77 CA12 (1.00) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL8088102 0.77 CA12 (1.00) KDM4ELMNATDP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197722-A1 ANTICANCER COMPOSITION INDUCING CELL SENESCENCE AND CELL DEATH OSTEONEUROGEN INC. (KR) 2024-06-20 US claimed
EP-4327811-A1 ANTICANCER COMPOSITION INDUCING CELL SENESCENCE AND CELL DEATH Osteoneurogen Inc. (KR) 2024-02-28 EP claimed
CN-117157074-A Anticancer composition for inducing cell aging and cell death 欧斯特奥纽罗根有限公司 2023-12-01 CN claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2022225259-A1 ANTICANCER COMPOSITION INDUCING CELL SENESCENCE AND CELL DEATH (주)오스티오뉴로젠 2022-10-27 WO claimed
EP-3760626-B1 NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT OSTEONEUROGEN INC (KR) 2022-05-18 EP claimed
US-11298353-B2 Anti-inflammatory composition OSTEONEUROGEN INC. (KR) 2022-04-12 US claimed
CN-106978350-B Aspergillus niger and application thereof in preparation of puerarin compounds 北京大学 2022-01-07 CN claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20100267823-A1 AURONES AS SELECTIVE PDE INHIBITORS AND THEIR USE IN NEUROLOGICAL CONDITIONS AND DISORDERS BIOTROPICS MALAYSIA BERHAD (MY) 2010-10-21 US claimed
WO-2010110647-A1 AURONES AS ESTROGEN RECEPTOR MODULATORS AND THEIR USE IN SEX HORMONE DEPENDENT DISEASES BIOTROPICS MALAYSIA BERHAD (MY) 2010-09-30 WO claimed
WO-2010110646-A1 AURONES AS SELECTIVE PDE INHIBITORS AND THEIR USE IN NEUROLOGICAL CONDITIONS AND DISORDERS BIOTROPICS MALAYSIA BERHAD (MY) 2010-09-30 WO claimed
US-7122573-B2 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents SRI INTERNATIONAL (US) 2006-10-17 US claimed
US-7109236-B2 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents SRI INTERNATIONAL (US) 2006-09-19 US claimed
EP-1581512-A2 ANALOGS OF GREEN TEA POLYPHENOLS AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS SRI INTERNATIONAL (US) 2005-10-05 EP claimed
US-20040192723-A1 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents SRI INTERNATIONAL 2004-09-30 US claimed
WO-2004052873-A9 ANALOGS OF GREEN TEA POLYPHENOLS AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS STANFORD RES INST INT (US) 2004-08-12 WO claimed
WO-2004052873-A2 ANALOGS OF GREEN TEA POLYPHENOLS AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS SRI INTERNATIONAL (US) 2004-06-24 WO claimed
US-20040110790-A1 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents SRI INTERNATIONAL 2004-06-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB KDM4E 4637/4885LMNA 344/4885TDP1 3469/4885
US-20040192723-A1 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents TEAD4, TEAD3, TEAD1 KDM4E 1321/4885LMNA 3961/4885TDP1 523/4885
US-20040110790-A1 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents TEAD4, TEAD3, TEAD1 KDM4E 1321/4885LMNA 3961/4885TDP1 523/4885
US-20240197722-A1 ANTICANCER COMPOSITION INDUCING CELL SENESCENCE AND CELL DEATH TP53, CASP3, BAX KDM4E 3375/4885LMNA 364/4885TDP1 362/4885
US-11298353-B2 Anti-inflammatory composition CCL2, CCL5, CCL11 KDM4E 4455/4885LMNA 3620/4885TDP1 3215/4885
US-20100267823-A1 AURONES AS SELECTIVE PDE INHIBITORS AND THEIR USE IN NEUROLOGICAL CONDITIONS AND DISORDERS PDE12, PDE3A, PDE7A KDM4E 1546/4885LMNA 2114/4885TDP1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.